Mayer Brown has added Scott Liebman and Dominick DiSabatino as partners in its Life Sciences practice, strengthening the firm’s capabilities across FDA regulatory matters, compliance, enforcement, transactions, and healthcare-related investigations.
Both lawyers join Mayer Brown from Sheppard, Mullin, Richter & Hampton. Liebman previously served as co-leader of that firm’s Life Sciences practice and leader of its FDA practice.
Liebman will serve as co-leader of Mayer Brown’s Life Sciences practice and leader of its FDA Regulatory and Enforcement practice. He will be based in New York and Washington, D.C., while DiSabatino will be based in Washington, D.C.
The appointments expand Mayer Brown’s ability to advise pharmaceutical, biotechnology, medical device, healthcare, and digital health companies as they navigate changing regulatory requirements, increased government scrutiny, scientific innovation, and a faster pace of transactions across the life sciences sector.
Liebman has decades of experience advising life sciences companies on FDA regulatory matters, compliance and enforcement issues, product development, investigations, M&A, licensing transactions, and other strategic business initiatives.
DiSabatino advises life sciences companies on complex FDA regulatory matters, research and development and commercial strategy, contracting, product launch readiness, internal and government investigations, corporate transactions, and enterprise-level healthcare compliance programs.
Mayer Brown said the additions are part of its continued investment in the life sciences sector and expand the firm’s multidisciplinary capabilities across litigation, investigations, regulatory counseling, and transactions.
KEY QUOTES:
“Scott and Dominick are exceptional lawyers whose practices align with growing client needs across the life sciences industry. Their expertise enhances our ability to advise clients on the complex regulatory, compliance, transactional, and enforcement issues they face and further strengthens our multidisciplinary life sciences platform.”
Michael Olsen, Co-Leader Of Mayer Brown’s Litigation & Dispute Resolution Practice
“The life sciences industry is facing increasingly complex and rapidly changing regulatory, compliance, and enforcement challenges that require practical, business-focused advice. Mayer Brown’s depth across litigation, investigations, regulatory counseling, and transactions creates a compelling platform for helping clients navigate those challenges. Dom and I are excited to join the firm and continue building its Life Sciences practice.”
Scott Liebman, Co-Leader Of Mayer Brown’s Life Sciences Practice And Leader Of Its FDA Regulatory And Enforcement Practice
“Scott and Dominick bring a leading life sciences practice to Mayer Brown, adding a significant new capability to our platform. They are highly regarded advisors whose experience and relationships will be an immediate asset to our clients. Their addition further expands our presence in the life sciences industry at a time of significant innovation and growth.”
Allison Aviki, Managing Partner Of Mayer Brown’s New York Office
